Skip to content
AnalystLens

AFLAC INC 8-K Report, Financial Results (Nov 4, 2025)

Reports
Earnings & Results·Regulation FD·Exhibits & Filings
Filing Date
Filed November 4, 2025
Period End
November 4, 2025
Security
AFL
In the record · 2016–202610-K1110-Q328-K114

AFL filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 114 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’17Jan ’17
  2. Material agreement8-K · Feb ’19Feb ’19
  3. Leadership change8-K · Oct ’22Oct ’22
  4. Leadership change8-K · Oct ’24Oct ’24

01—Abstract

Summary

Summary of the 8-K filed November 4, 2025. Cited figures are marked; the original filing is the authoritative source.

Aflac reported third-quarter 2025 net earnings of $1.6 billiona, or $3.08 per diluted share, versus a net loss of $93 million a year earlier.

The swing is driven mainly by net investment gains of $275 millionb this quarter compared with net investment losses of $1.4 billion in Q3 2024. The more important figure for investors is adjusted earnings, which rose 9.6% to $1.3 billion, and adjusted EPS, which rose 15.3% to $2.49. Adjusted EPS excludes net investment gains and losses, so it better reflects the underlying insurance business.

Adjusted ROE was 19.1%, or 22.1% excluding foreign currency remeasurement. The quarter was helped by a large favorable reserve remeasurement. Management said the assumption update added about $0.76c to EPS, with reserve remeasurement gains of $580 million.

Aflac Japan's pretax margin reached 52.2%, versus 44.7% a year earlier, and management attributed much of that to the actuarial unlock rather than to run-rate improvement. Underlying premium trends are softer: Japan's net earned premiums fell 4.0%, and underlying earned premiums fell 1.2%. Aflac U.S. net earned premiums grew 2.5% and its pretax margin was 21.7%, although the U.S. expense ratio rose on a one-time $21 milliond contract termination fee.

Capital deployment remained strong. The company repurchased $1.0 billion of stock, a record for the company, and declared a fourth-quarter dividend of $0.58 per share, extending its 43-year streak of annual dividend increases. Management raised its 2025 Japan benefit ratio range to 58% to 60% and expects a Japan pretax margin of 35% to 38%, while the U.S. guidance is unchanged.

Holding company liquidity was $4.5 billion, and leverage was 22.0%, within the 20% to 25% target. Investors should weigh the strong headline earnings against the reliance on favorable reserve and actuarial effects, along with the 2025 cumulative yen effect and the June 2025 network security incident.

02—Key points

Key Highlights

  1. Q3 2025 net earnings of $1.6 billion ($3.08 diluted EPS) versus a $93 million net loss in Q3 2024, driven mainly by net investment gains of $275 million.
  2. Adjusted EPS rose 15.3% to $2.49 and adjusted earnings rose 9.6% to $1.3 billion, which better reflects the core insurance operations.
  3. Reserve remeasurement gains of $580 million and a $0.76 EPS benefit from the Q3 assumption update materially helped earnings and are not likely to recur at this level.
  4. Aflac Japan pretax adjusted earnings rose 13.1% in yen, and the pretax margin reached 52.2%, though management attributed much of that to the actuarial unlock; underlying Japan earned premiums declined 1.2%.
  5. Aflac U.S. pretax adjusted earnings rose 7.1% to $375 million, with a 21.7% margin, but the expense ratio rose 90 basis points on a one-time $21 million termination fee.
  6. Record $1.0 billion share repurchase in Q3; $0.58 quarterly dividend declared, extending the 43-year streak of dividend increases.
  7. Raised the 2025 Japan benefit ratio range to 58% to 60%; U.S. guidance unchanged, with a pretax margin at the upper end of 17% to 20%.

03—Questions

Frequently Asked Questions

  1. Why did reported net earnings swing so sharply versus last year?

    Q3 2024 included net investment losses of $1.4 billion, while Q3 2025 had net investment gains of $275 million. Because net investment gains and losses are volatile, adjusted earnings, which exclude them, are a better gauge of underlying performance, and those rose 9.6%.

  2. How much of the quarter's earnings came from one-time or non-recurring items?

    Reserve remeasurement gains of $580 million, largely from the assumption update, boosted results; management estimated the total net impact of the Q3 assumption update at about $0.76 per share. The Japan pretax margin of 52.2% was also described as notably driven by the actuarial unlock, so investors should not extrapolate that margin.

  3. Is the underlying business growing?

    Growth is modest. U.S. net earned premiums grew 2.5% and sales rose 2.8%, but Japan net earned premiums fell 4.0% in yen terms, and underlying Japan earned premiums declined 1.2%. Japan sales rose 11.8%, driven by the Miraito cancer product, which suggests future premium trends may improve.

  4. What does the capital and dividend position look like?

    The company repurchased $1.0 billion of stock in the quarter and declared a $0.58 dividend payable December 1, 2025. It ended the quarter with $4.5 billion of unencumbered holding company liquidity, leverage of 22.0% within its 20% to 25% target, an estimated combined U.S. RBC ratio above 600%, and a Japan ESR above 250%.

  5. Did management change its 2025 outlook?

    Management raised its Japan benefit ratio expectation to 58% to 60%, citing the 2025 LDTI assumption unlock and lower benefit ratios on new business, and now expects the Japan pretax profit margin at 35% to 38%. The U.S. benefit ratio, expense ratio, and pretax margin ranges were reiterated.

04—Continue

← View all 8-K filings